The accelerator targets microbials and provides feasibility grants, which aligns loosely with the venture’s focus on drug‑resistance prediction for antimicrobial resistance. However, the programme is product‑centric and may prioritize wet‑lab microbial development over pure AI/computational platforms, so the fit is moderate.